267 related articles for article (PubMed ID: 18751439)
21. Preoperative PSA is still predictive of cancer volume and grade in late PSA era.
Figler BD; Reuther AM; Dhar N; Levin H; Magi-Galluzzi C; Zhou M; Klein EA
Urology; 2007 Oct; 70(4):711-6. PubMed ID: 17991542
[TBL] [Abstract][Full Text] [Related]
22. Fluctuating prostate-specific antigen levels in patients with initial negative biopsy: should we be reassured?
Celhay O; de la Taille A; Salomon L; Doré B; Irani J
BJU Int; 2007 May; 99(5):1028-30. PubMed ID: 17324221
[TBL] [Abstract][Full Text] [Related]
23. Investigative clinical study on prostate cancer part VI: Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
Porcaro AB; Migliorini F; Petrozziello A; Sava T; Romano M; Caruso B; Cocco C; Ghimenton C; Zecchinini Antoniolli S; Lacola V; Rubilotta E; Monaco C; Comunale L
Urol Int; 2012; 88(2):150-7. PubMed ID: 22205171
[TBL] [Abstract][Full Text] [Related]
24. Absence of relationship between steroid hormone levels and prostate cancer tumor grade.
Sher DJ; Mantzoros C; Jacobus S; Regan MM; Lee GS; Oh WK
Urology; 2009 Feb; 73(2):356-61; discussion 361-2. PubMed ID: 19036418
[TBL] [Abstract][Full Text] [Related]
25. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.
Bittner N; Merrick GS; Andreini H; Taubenslag W; Allen ZA; Butler WM; Anderson RL; Adamovich E; Wallner KE
Urology; 2009 Jul; 74(1):171-6. PubMed ID: 19232691
[TBL] [Abstract][Full Text] [Related]
26. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK
Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
[TBL] [Abstract][Full Text] [Related]
27. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
[TBL] [Abstract][Full Text] [Related]
28. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
[TBL] [Abstract][Full Text] [Related]
29. Association between prostate cancer and serum testosterone levels.
Zhang PL; Rosen S; Veeramachaneni R; Kao J; DeWolf WC; Bubley G
Prostate; 2002 Nov; 53(3):179-82. PubMed ID: 12386917
[TBL] [Abstract][Full Text] [Related]
30. [Clinical impact of body mass index on prostate biopsy in patients with intermediate PSA levels].
Sekita N; Suzuki H; Kamijima S; Chini K; Fujimura M; Mikami K
Hinyokika Kiyo; 2008 Jul; 54(7):479-83. PubMed ID: 18697492
[TBL] [Abstract][Full Text] [Related]
31. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.
Steyerberg EW; Roobol MJ; Kattan MW; van der Kwast TH; de Koning HJ; Schröder FH
J Urol; 2007 Jan; 177(1):107-12; discussion 112. PubMed ID: 17162015
[TBL] [Abstract][Full Text] [Related]
32. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE
Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534
[TBL] [Abstract][Full Text] [Related]
33. [Pathological features of prostate cancer in Chinese cohort detected through mass screening and their relationships with serum prostate specific antigen].
Gao HW; Li YL; Wu S; Wang YS; Pan YZ; Zhang L; Zhao XJ
Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(15):1300-2. PubMed ID: 12930681
[TBL] [Abstract][Full Text] [Related]
34. A direct comparison of the diagnostic accuracy of three prostate cancer nomograms designed to predict the likelihood of a positive initial transrectal biopsy.
Ouzaid I; Yates DR; Hupertan V; Mozer P; Chartier-Kastler E; Haertig A; Bitker MO; Rouprêt M
Prostate; 2012 Aug; 72(11):1200-6. PubMed ID: 22213470
[TBL] [Abstract][Full Text] [Related]
35. Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Nishimoto K; Nakashima J; Hashiguchi A; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M; Murai M
Int J Urol; 2008 Jun; 15(6):520-3. PubMed ID: 18422574
[TBL] [Abstract][Full Text] [Related]
36. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice.
Dong F; Kattan MW; Steyerberg EW; Jones JS; Stephenson AJ; Schröder FH; Klein EA
J Urol; 2008 Jul; 180(1):150-4; discussion 154. PubMed ID: 18485398
[TBL] [Abstract][Full Text] [Related]
37. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
[TBL] [Abstract][Full Text] [Related]
38. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
Schröder FH; Roobol MJ
Curr Opin Urol; 2009 May; 19(3):227-31. PubMed ID: 19357513
[TBL] [Abstract][Full Text] [Related]
39. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
[TBL] [Abstract][Full Text] [Related]
40. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I
Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
